Mereo BioPharma EBITDA vs. Retained Earnings
| 0A9G Stock | 3.67 0.23 5.90% |
For Mereo BioPharma profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Mereo BioPharma to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Mereo BioPharma Group utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Mereo BioPharma's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Mereo BioPharma Group over time as well as its relative position and ranking within its peers.
Mereo |
Mereo BioPharma Group Retained Earnings vs. EBITDA Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Mereo BioPharma's current stock value. Our valuation model uses many indicators to compare Mereo BioPharma value to that of its competitors to determine the firm's financial worth. Mereo BioPharma Group is number one stock in ebitda category among its peers. It also is number one stock in retained earnings category among its peers . At this time, Mereo BioPharma's Retained Earnings are comparatively stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Mereo BioPharma's earnings, one of the primary drivers of an investment's value.Mereo Retained Earnings vs. EBITDA
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Mereo BioPharma |
| = | (37.48 M) |
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Retained Earnings is a balance sheet account that refers to the portion of company income that is retained by the firm. In other words, it is a part of earnings that is not paid out as dividends or otherwise distributed to owners. Retained Earnings are calculated by adding net income to last period retained earnings and subtracting any dividends paid to owners.
Mereo BioPharma |
| = | (331.16 M) |
Retained Earnings shows how the firm utilizes its profits over time. In simple terms, investors can think of retained earnings as the amount of profit the company has reinvested in the business since its inceptions. However the methodology to make a decision over how much profit to retain is different between companies in different industries. For example, growing industries tend to retain more of their earnings than more matured industries as they need more assets investment to sustain their growth.
Mereo Retained Earnings Comparison
Mereo BioPharma is currently under evaluation in retained earnings category among its peers.
Mereo BioPharma Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Mereo BioPharma, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Mereo BioPharma will eventually generate negative long term returns. The profitability progress is the general direction of Mereo BioPharma's change in net profit over the period of time. It can combine multiple indicators of Mereo BioPharma, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Net Loss | -39.3 M | -41.3 M | |
| Income Tax Expense | -2.2 M | -2.3 M | |
| Net Loss | -39.3 M | -41.3 M | |
| Change To Netincome | -15.1 M | -14.3 M |
Mereo Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Mereo BioPharma. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Mereo BioPharma position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Mereo BioPharma's important profitability drivers and their relationship over time.
Use Mereo BioPharma in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Mereo BioPharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Mereo BioPharma will appreciate offsetting losses from the drop in the long position's value.Mereo BioPharma Pair Trading
Mereo BioPharma Group Pair Trading Analysis
The ability to find closely correlated positions to Mereo BioPharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Mereo BioPharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Mereo BioPharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Mereo BioPharma Group to buy it.
The correlation of Mereo BioPharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Mereo BioPharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Mereo BioPharma Group moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Mereo BioPharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Mereo BioPharma position
In addition to having Mereo BioPharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Beers Thematic Idea Now
Beers
Companies involved in production and distribution of domestic and international beer. The Beers theme has 37 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Beers Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Mereo Stock Analysis
When running Mereo BioPharma's price analysis, check to measure Mereo BioPharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mereo BioPharma is operating at the current time. Most of Mereo BioPharma's value examination focuses on studying past and present price action to predict the probability of Mereo BioPharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mereo BioPharma's price. Additionally, you may evaluate how the addition of Mereo BioPharma to your portfolios can decrease your overall portfolio volatility.